| Name | Title | Contact Details |
|---|
At Luitpold Animal Health, we are totally committed to advancing the cause of better animal health.
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia
CPL is a leading contract development and manufacturing organization (CDMO) that provides development, manufacturing, packaging, and testing of non-sterile liquid and semi-solid pharmaceutical and regulated OTC products.
Esschem is the worlds most respected manufacturer of specialty acrylic polymers and monomers for medical and cosmetic uses.
The Flowr Corporation is a global cannabis company that exists to cultivate better people, plants and products. Based in Toronto, we operate globally in Canada, Europe and Australia. In Canada, our operating campus in Kelowna, BC is situated in the Okanagan Valley, an epicentre of cannabis cultivation. This campus produces recreational and medicinal cannabis from a purpose-built, GMP-designed indoor cultivation facility, an outdoor and greenhouse cultivation site, and (soon to open) state-of-the-art R&D facility. Internationally, The Flowr Corporation will meet growing global medicinal cannabis demand through its subsidiary Holigen. Licensed to cultivate in Portugal, Holigen will operate GMP-designed cultivation facilities in both Portugal and Australia. Our goal is to be the #1 choice of consumers and patients alike, and our established experts in cannabis cultivation, regulated industries and consumer goods aim to meet that goal responsibly, everywhere we operate.